Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%

May.08
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.

Key Takeaways

  • Turning Point Brands reported first-quarter 2026 total consolidated net sales of $124.3 million, up 16.8%.
  • Modern Oral net sales increased 133% to $52.0 million, accounting for 42% of total company net sales.
  • Stoker’s segment net sales rose 48.1% to $87.6 million, accounting for 70% of quarterly net sales.
  • Zig-Zag segment net sales declined 22.4% to $36.7 million, accounting for 30% of quarterly net sales.
  • The company raised full-year Modern Oral net sales guidance to $210 million to $225 million, from $180 million to $190 million.

2Firsts, May 8, 2026

 

According to Turning Point Brands, Inc.’s first-quarter 2026 earnings release, the company reported total consolidated net sales of $124.3 million for the quarter ended March 31, 2026, up 16.8% year on year. Gross profit increased 14.6% to $68.3 million. 

 

Net income declined 19.0% to $11.7 million, while adjusted EBITDA decreased 6.5% to $25.9 million. Diluted EPS was $0.60 and adjusted diluted EPS was $0.76, compared with $0.79 and $0.91, respectively, in the same period a year earlier.

 

Modern Oral net sales increased 133%

 

The company said Modern Oral net sales increased 133% to $52.0 million in the first quarter of 2026, accounting for 42% of total company net sales, up from 21% in the first quarter of 2025.

 

Company raised full-year Modern Oral guidance

 

For 2026, Turning Point Brands raised its Modern Oral sales guidance. 

 

The company now expects full-year Modern Oral gross sales of $280 million to $300 million, up from previous guidance of $220 million to $240 million.

 

 It expects full-year Modern Oral net sales of $210 million to $225 million, up from $180 million to $190 million. 

 

The company also introduced full-year adjusted EBITDA guidance of $70 million to $90 million, inclusive of investments in Modern Oral sales, marketing and trade promotions.

 

CEO said Q1 was driven by Modern Oral momentum

 

President and CEO Graham Purdy said the first quarter was driven by continued momentum in Modern Oral and disciplined execution across the portfolio. He said the company is investing in brands, commercial capabilities and consumer reach to capture share in white pouch, including through its recently announced TKO partnership featuring UFC.

 

Stoker’s segment net sales increased 48.1%

 

Stoker’s products segment net sales were $87.6 million in the first quarter, up 48.1% year on year and representing 70% of total quarterly net sales. The company said the increase was driven by triple-digit growth in Modern Oral net sales. Segment gross profit increased 39.1% to $47.3 million. Gross profit as a percentage of net sales fell to 54.0% from 57.5% a year earlier, primarily driven by margin contribution from Modern Oral products.

 

Zig-Zag segment net sales decreased 22.4%

 

Zig-Zag products segment net sales were $36.7 million, down 22.4% year on year and representing 30% of total quarterly net sales. The company said the decline was driven primarily by lower U.S. papers and wraps shipments. 

 

Segment gross profit decreased 18.1% to $20.9 million. Gross profit as a percentage of net sales rose to 57.1% from 54.1% a year earlier, driven primarily by product mix.

 

Sales and marketing investments increased SG&A expenses

 

The company said first-quarter investment focused on sales and marketing efforts to support distribution and brand building. 

 

Consolidated selling, general and administrative expenses increased 53.2% year on year to $55.8 million, including Modern Oral-related sales and marketing investments and increased outbound freight costs.

 

Ending cash was $192.4 million

 

As of March 31, 2026, ending cash was $192.4 million and net debt was $101.4 million. The company ended the quarter with total liquidity of $265.0 million, comprising $192.4 million in cash and $72.6 million of asset-backed revolving credit facility capacity.

 

Financial statements showed lower operating income

 

According to the consolidated statements of income on page 5 of the release, operating income was $12.5 million in the first quarter of 2026, compared with $23.2 million in the first quarter of 2025. Net income attributable to Turning Point Brands, Inc. was $11.7 million, compared with $14.4 million a year earlier.

 

Operating cash flow turned negative

 

According to the cash flow statement on page 7 of the release, the company used $22.3 million in cash from operating activities in the first quarter of 2026, compared with $17.4 million provided by operating activities in the same period of 2025. During the period, inventories increased by $21.7 million and accrued liabilities and other items decreased by $21.7 million.

 

Adjusted EBITDA was $25.9 million

 

According to Schedule A on page 9, adjusted EBITDA was $25.9 million in the first quarter of 2026, compared with $27.7 million in the same period of 2025. 

 

Adjustments included a $5.9 million tariff adjustment, $2.9 million in stock-based compensation, $0.6 million in manufacturing start-up costs and $0.3 million in FDA PMTA-related costs.

 

Adjusted net income was $14.8 million

 

According to Schedule B on page 10, adjusted net income was $14.8 million in the first quarter of 2026, and adjusted diluted EPS was $0.76. In the first quarter of 2025, adjusted net income was $16.7 million and adjusted diluted EPS was $0.91.

 

Company said products are available in more than 220,000 retail outlets

 

Turning Point Brands said it manufactures, markets and distributes branded consumer products including alternative smoking accessories and consumables with active ingredients. Its brand portfolio includes Zig-Zag, Stoker’s, FRE and ALP. 

 

The company said its products are available in more than 220,000 retail outlets in North America and on sites including zigzag.com, frepouch.com and alppouch.com.

 

Image Source: Turning Point Brands

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Russian Vape Compromise Faces First Hurdles
Special Report | Russian Vape Compromise Faces First Hurdles
Russia’s regional vape-ban model is facing early legal and political tests, as Perm Krai moves ahead before federal legislation is fully adopted. The case highlights uncertainty over regional authority, concerns from business groups about market fragmentation, and the risk that pressure against regional bans could revive calls for a stricter nationwide prohibition.
Industry Insight
May.28
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Group reported its first-quarter 2026 results on April 30. Net revenues were $5.43 billion, up 3.2% year on year, while revenues net of excise taxes were $4.76 billion, up 5.3%. Reported diluted EPS was $1.30, up more than 100%, and adjusted diluted EPS was $1.32, up 7.3%.
May.06 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai